Chardan Capital Maintains Buy on Dyne Therapeutics, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has reaffirmed its Buy rating on Dyne Therapeutics (NASDAQ:DYN) and increased the price target from $20 to $31.
March 08, 2024 | 8:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has upgraded its price target for Dyne Therapeutics from $20 to $31 while maintaining a Buy rating.
The upgrade in price target by Chardan Capital is a strong positive signal for investors, indicating a bullish outlook on Dyne Therapeutics. This could lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100